Article
Clinical Neurology
Feng Gao, Xinyi Lv, Linbin Dai, Qiong Wang, Peng Wang, Zhaozhao Cheng, Qiang Xie, Ming Ni, Yan Wu, Xianliang Chai, Wenjing Wang, Huaiyu Li, Feng Yu, Yuqin Cao, Fang Tang, Bo Pan, Guoping Wang, Kexue Deng, Shicun Wang, Qiqiang Tang, Jiong Shi, Yong Shen
Summary: This study tested the utility of the A/T/N system in the Chinese population and investigated core AD biomarkers in a newly established Chinese cohort. The results showed that CSF A beta 42/A beta 40, CSF p-tau, and plasma p-tau had high concordance in discriminating between AD and non-AD dementia or elderly controls. A combination of plasma p-tau, APOE genotype, and MRI measures accurately predicted amyloid PET status.
ALZHEIMERS & DEMENTIA
(2023)
Article
Neurosciences
Malin Wennstrom, Shorena Janelidze, K. Peter R. Nilsson, Geidy E. Serrano, Thomas G. Beach, Jeffrey L. Dage, Oskar Hansson
Summary: Recent studies have identified p-tau217 as a potential plasma biomarker for Alzheimer's disease (AD), but its relationship with specific brain pathological events is still unclear. This study found that p-tau217 is mainly found in neurofibrillary tangles and neuropil threads, and differs from other p-tau variants. Individuals with a high likelihood of AD had significantly higher p-tau217 levels in specific brain areas and these levels correlated with amyloid-beta and NFT brain load. Additionally, the levels of p-tau217 in plasma correlated with its concentrations in individuals with amyloid plaques.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2022)
Article
Geriatrics & Gerontology
Jemma Hazan, Duncan Alston, Nick C. Fox, Robert Howard
Summary: Plasma p-tau181 levels may serve as a useful tool in the diagnosis of Alzheimer's disease, especially in clinical settings where biomarkers are less commonly used. However, its utility as a diagnostic aid may be limited in the very oldest-old population.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
(2022)
News Item
Biochemistry & Molecular Biology
Thiago Carvalho
Summary: Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron's gene-editing treatment, which reduced levels of transthyretin in patients.
Article
Biochemistry & Molecular Biology
Beatrice Balboni, Shailesh Kumar Tripathi, Marina Veronesi, Debora Russo, Ilaria Penna, Barbara Giabbai, Tiziano Bandiera, Paola Storici, Stefania Girotto, Andrea Cavalli
Summary: In this study, we identified promising GSK-3 beta inhibitors through 1D F-19 NMR fragment screening and biophysical assays. We also proposed an alternative screening workflow to overcome the limitations of common GSK-3 beta inhibitors and found selective inhibitors and/or inhibitors capable of modulating GSK-3 beta activity without complete inhibition.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Clinical Neurology
Dallas P. Veitch, Michael W. Weiner, Paul S. Aisen, Laurel A. Beckett, Charles DeCarli, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, Susan M. Landau, John C. Morris, Ozioma Okonkwo, Richard J. Perrin, Ronald C. Petersen, Monica Rivera-Mindt, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga, Duygu Tosun, John Q. Trojanowski
Summary: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has been a long-term research project, providing extensive data and samples for understanding the progression and biomarkers of Alzheimer's disease, and improving the efficacy of clinical trials. Studies have identified key factors in the progression of AD and opened up new possibilities for diagnostic and prognostic models.
ALZHEIMERS & DEMENTIA
(2022)
Article
Geriatrics & Gerontology
Kai-Wen Wang, Yu-Xin Yuan, Bin Zhu, Yi Zhang, Yi-Fang Wei, Fan-Shuo Meng, Shun Zhang, Jing-Xuan Wang, Ji-Yuan Zhou
Summary: 15 SNPs were identified to be statistically significantly associated with different quantitative biomarkers of Alzheimer's disease (AD) in this X chromosome-wide association study. Follow-up molecular genetics studies are needed to confirm their relationship with AD, and these findings expand understanding of the role of the X chromosome in disease susceptibility.
FRONTIERS IN AGING NEUROSCIENCE
(2023)
Article
Chemistry, Multidisciplinary
Le Hoang Anh, Gwang Hyun Yu, Dang Thanh Vu, Jin Sul Kim, Jung Il Lee, Jun Churl Yoon, Jin Young Kim
Summary: This study proposes a lightweight temporal convolutional network (TCN) model for resource-constrained systems, which achieves the same accuracy as the heavy counterpart through a stride-dilation mechanism. Experimental results show that the model reduces the mean squared error by 32.7% compared to the baseline TCN.
APPLIED SCIENCES-BASEL
(2022)
Article
Geriatrics & Gerontology
Fuqiang Qian, Jian Liu, Hongyu Yang, Haohao Zhu, Zhiqiang Wang, Yue Wu, Zaohuo Cheng
Summary: This study investigates the association between plasma BDNF levels and Alzheimer's disease, as well as its influencing factors. The results show significant differences in BDNF levels among different patient groups and its correlation with cognitive impairment and clinical diagnosis. Age, education, occupation, and sample source also have an impact on BDNF levels.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Wenjing Li, Yinhua Zhou, Zhaofan Luo, Rixin Tang, Yuxuan Sun, Qiangsheng He, Bin Xia, Kuiqing Lu, Qinghua Hou, Jinqiu Yuan
Summary: This study aims to construct a lipid score system to predict the risk of progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD). The results showed that the lipid score system based on serum lipidomics can accurately predict the progression risk from MCI to AD.
Review
Chemistry, Medicinal
Sukriti Srivastava, Razi Ahmad, Sunil Kumar Khare
Summary: Alzheimer's disease is a neurodegenerative disorder that impairs mental ability development and interrupts neurocognitive function. Current treatments only provide symptomatic relief with no cure available yet. Nanotechnology and stem cell-based therapy are seen as promising approaches to overcome the obstacles in treating AD.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Geriatrics & Gerontology
Aladdin H. Shadyab, Linda K. McEvoy, Steve Horvath, Eric A. Whitsel, Stephen R. Rapp, Mark A. Espeland, Susan M. Resnick, JoAnn E. Manson, Jiu-Chiuan Chen, Brian H. Chen, Wenjun Li, Kathleen M. Hayden, Wei Bao, Cynthia D. J. Kusters, Andrea Z. LaCroix
Summary: The study examined the association between epigenetic age acceleration and cognitive impairment, finding that intrinsic AgeAccel was not significantly associated with cognitive impairment overall, but was associated with impairment among women who developed coronary heart disease.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2022)
Review
Clinical Neurology
Bruce Albala, Eline Appelmans, Ramona Burress, Susan De Santi, Theresa Devins, Gregory Klein, Veronika Logovinsky, Gerald P. Novak, Kim Ribeiro, Mark E. Schmidt, Adam J. Schwarz, David Scott, Sergey Shcherbinin, Eric Siemers, Alessio Travaglia, Christopher J. Weber, Leah White, Julie Wolf-Rodda, Aparna Vasanthakumar
Summary: This article reviews the major activities of the ADNI Private Partners Scientific Board (PPSB), focusing on the impact it has had on biomarker discovery and validation in Alzheimer's disease. It also provides an outlook on future PPSB activities and potential research gaps to be filled.
ALZHEIMERS & DEMENTIA
(2023)
Article
Medicine, General & Internal
Longfei Jia, Min Zhu, Jianwei Yang, Yana Pang, Qi Wang, Ying Li, Tingting Li, Fangyu Li, Qigeng Wang, Yan Li, Yiping Wei
Summary: This study suggests that a panel of microRNAs in serum can serve as a promising substitute for traditional measurement of P-tau/A beta 42 in CSF as an effective biomarker of Alzheimer's disease (AD), successfully differentiating AD from other dementias.
Article
Gastroenterology & Hepatology
Dan Turner, Amanda Ricciuto, Ayanna Lewis, Ferdinando D'Amico, Jasbir Dhaliwal, Anne M. Griffiths, Dominik Bettenworth, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Juergen Schoelmerich, Willem Bemelman, Silvio Danese, Jean Yves Mary, David Rubin, Jean-Frederic Colombel, Laurent Peyrin-Biroulet, Iris Dotan, Maria T. Abreu, Axel Dignass
Summary: STRIDE-II presents treatment targets for both adult and pediatric IBD, including long-term and short-term goals. These targets cover aspects such as clinical response, endoscopic healing, quality of life, and growth, providing guidance for improving patient outcomes.